Anacor compounds meet atopic dermatitis endpoints

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) said topical twice-daily 2% AN2728 and twice-daily 1% AN2898 for six weeks each met the primary endpoint in a Phase IIa trial to treat atopic dermatitis. AN2728 and AN2898 each led to a significantly greater proportion of patient lesions showing improvement at day 28 vs. vehicle-treated control lesions (64% and 71%, respectively, vs. 24% and 14%; p=0.05 and p=0.01). The double-blind, Australian trial enrolled 46 patients. ...